title: Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
abstract: BACKGROUND
  For many patients, adhering to postmenopausal osteoporosis treatment is a challenge. Higher treatment satisfaction is associated with greater persistence with these therapies, which is associated with better outcomes.
  
  
  OBJECTIVE
  This study aimed to evaluate the change in treatment satisfaction in postmenopausal women who were suboptimally adherent to daily or weekly oral bisphosphonates and who transitioned to denosumab vs a monthly oral bisphosphonate.
  
  
  METHODS
  Pooled data of outpatients from two international, multicenter, randomized, open-label studies were analyzed.
  
  
  METHODS
  Postmenopausal women (n = 1703) age 55 years or greater with low bone mineral density who were suboptimally adherent with prior oral bisphosphonate therapy, as assessed by the Osteoporosis-Specific Morisky Medication Adherence Scale, were included in the study.
  
  
  METHODS
  Patients received denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor-kappa B ligand, 60 mg s.c. every 6 months vs the oral bisphosphonates ibandronate or risedronate, 150 mg once monthly for 12 months.
  
  
  METHODS
  Change in treatment satisfaction scores from baseline to months 6 and 12 were measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is a validated tool that measures perception of four domains of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction.
  
  
  RESULTS
  Patients in both treatment groups showed improvement from baseline for all four TSQM domains at 6 and 12 months. However, the denosumab group had significantly (all P < .001) greater improvements among all four TSQM domains at 6 and 12 months compared with the oral bisphosphonate group.
  
  
  CONCLUSIONS
  Women with low adherence to oral bisphosphonates reported greater treatment satisfaction when transitioned to denosumab vs switching to a monthly oral bisphosphonate.
authors.affiliation: Instituto Palacios (S.P.), 9-28009 Madrid, Spain; Amgen (I.A., P.-R.H.), Thousand Oaks, California 91320; Clinical Research Center of North Texas (S.B.), Denton, Texas 76210; VieCuri Medical Center and Maastricht University (J.P.V.), 6200 MD Maastricht, Netherlands; Amgen (I.F.), Cambridge CB4 0WD, United Kingdom; and Laval University and CHU de Québec Research Centre (J.P.B.), Québec City, Canada G1V 4G2.
authors.forename: Santiago
authors.initials: S
authors.lastname: Palacios
authors.forename: Irene
authors.initials: I
authors.lastname: Agodoa
authors.forename: Sydney
authors.initials: S
authors.lastname: Bonnick
authors.forename: Joop P
authors.initials: JP
authors.lastname: Van den Bergh
authors.forename: Irene
authors.initials: I
authors.lastname: Ferreira
authors.forename: Pei-Ran
authors.initials: PR
authors.lastname: Ho
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Brown
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D057915:Drug Substitution; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D017060:Patient Satisfaction; D000068296:Risedronic Acid; D016896:Treatment Outcome; D016903:Drug Monitoring
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid